Two Sigma Securities’s SAB Biotherapeutics SABS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$49.7K Buy
+15,663
New +$57K ﹤0.01% 1409
2023
Q3
– Sell
-1,287
Closed -$10.7K – 3404
2023
Q2
$10.7K Sell
1,287
-57
-4% -$467 ﹤0.01% 2587
2023
Q1
$5.91K Buy
+1,344
New +$8.5K ﹤0.01% 2514

Other funds holding SABS

Two Sigma Securities's SABS Position: Q3 2026 in Review

Two Sigma Securities opened a new position in SAB Biotherapeutics (SABS) in Q3 2026: 15,663 shares worth $49.7K. The stake represents ﹤0.01% of the portfolio and ranks #1409 among its holdings. This is a return to the name: Two Sigma Securities previously reported a position in SABS as recently as Q2 2023.

Two Sigma Securities first reported a position in SABS in Q1 2023 and has held it in 3 quarters since. 76 funds tracked by Wall St. Rank hold SABS as of Q3 2026.

  • Two Sigma Securities held 15,663 shares of SAB Biotherapeutics worth $49.7K as of Q3 2026.
  • SAB Biotherapeutics was a new Two Sigma Securities position in Q3 2026.
  • SAB Biotherapeutics made up ﹤0.01% of Two Sigma Securities's portfolio in Q3 2026, its #1409 holding.
  • Two Sigma Securities first reported a position in SAB Biotherapeutics in Q1 2023 and has held it in 3 quarters since.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2026.

Based on Two Sigma Securities's 13F filing for Q3 2026, filed 16 Nov 2026.